Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01343797
Other study ID # IGNUT PEC10513
Secondary ID
Status Active, not recruiting
Phase N/A
First received April 20, 2011
Last updated April 27, 2011
Start date February 2011
Est. completion date May 2011

Study information

Verified date April 2011
Source CRITT Bio-Industries
Contact n/a
Is FDA regulated No
Health authority France : AFSSAPS
Study type Interventional

Clinical Trial Summary

The aim of the study is to determine glycemic and insulinemic index of 2 sweet syrups : FructiLight® and fruit Fructo-oligosaccharides in sweet matrix compared to glucose.


Description:

12 male and female healthy adults are included in the study. During 5 separated visits subjects consume either 50 g of glucose in water (3 glucose response tests) or portion of syrup supply the equivalent of 50 g of glycaemic carbohydrates (2 syrup response tests).

Experimental sessions last 3 hours with 9 veinous and capillary blood taking. The experimental meals are served at t0 and are consumed between 12 and 15 minutes maximum. At time -5, 0, 15, 30, 45, 60, 90, 120 and 180 minutes, glucose is measured out on capillary blood and insulin is measured out on venous blood.

The glycemic index and Insulinemic index determination of the 2 syrups start by the calculation for each glycemia and insulinemia responses of the AUC over 120 min. The AUC(0-120min) is computed following the FAO recommendation (cf. FAO/WHO 1998), i.e. using the trapezoidal incremental method and not taking into account the area beneath the fasting concentration. then GI and II values expressed in percentage are calculated by dividing the AUC(0-120min) for test syrup products by the AUC(0-120min) for the glucose reference and multiplying by 100.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date May 2011
Est. primary completion date March 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Aged between 18 to 50 years (limits included

- With a BMI between 19 and 25 kg/m² (limits included)

- Non-smoker

- Non-menopausal female with reliable contraception for two cycles before the beginning of the study and agreeing to keep it during the entire duration of the study

- Capable and willing to conform to the protocol and accepting to give his written informed consent

- Registered to Social Security System

- Accepting to be registered on the Volunteers in biomedical research file

After biological analysis, the subjects will be included on the following criteria :

- Fasting blood sugar level < 1,1 g/L

- Blood sugar level 120 minutes after 75g glucose intake < 1.4 g/L

- Complete blood count without significant clinically abnormality according to the investigator

- ASAT < 1,55 µkat/L

- ALAT < 1,7 µkat/L

- GGT < 2,55 µkat/L

- 45 < Creatinine < 104 µmol/L

- 1.7 < Urea < 8.3 mmol/L

Exclusion Criteria:

- Known food allergy, in particular to one of the tested products' components or to related products

- Personal history of hypercholesterolemia, high blood pressure, diabetes or glucose intolerance

- Renal insufficiency

- Liver disorders ongoing

- Gastrointestinal disorders, clinically significant according the investigator

- Use of medications which could affect lipidic or carbohydrate metabolism

- Disease or medication with impact on nutrients digestion and absorption

- Pregnant or breastfeeding women

- General anaesthetic in the month before the study

- Presenting a psychological or linguistic incapability to sign the informed consent

- Refusing to sign the informed consent

- Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision

- Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros

- Impossible to contact in case of emergency

- Major or medical or surgical event with hospitalization in the last 3 months

- Taking part in an-other clinical trial or being in the exclusion period of a previous clinical trial

Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Other:
Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup
One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water

Locations

Country Name City State
France Biofortis Nantes Pays de La Loire

Sponsors (3)

Lead Sponsor Collaborator
CRITT Bio-Industries BioFortis, NUTRITIS

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the glycemia Curve over 120 min (AUC 0-120min) Syrup glycemic response compare to glucose glycemic response. Measure with glucometer at time 15, 30, 45, 60, 90, 120 (and 180 minutes) after the intake of 50g of glucose equivalent from the products (syrup or glucose). AUC(0-120min) calculation is computed following the FAO recommendation (cf. FAO/WHO 1998), i.e. using the trapezoidal incremental method and not taking into account the area beneath the fasting concentration. 120 minutes after intake by test No
Secondary Area Under the insulinemia Curve over 120 min (AUC 0-120min) Syrup insulinemia response compare to glucose insulinemia response. Measure at time 15, 30, 45, 60, 90, 120 (and 180 minutes) after the intake of 50g of glucose equivalent from the products (syrup or glucose). AUC(0-120min) calculation is computed following the FAO recommendation (cf. FAO/WHO 1998), i.e. using the trapezoidal incremental method and not taking into account the area beneath the fasting concentration. 120 minutes after intake by test No
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1